Exploring the tolerability of an adjuvant dietary therapy in Ulcerative Colitis

niversity of Adelaide0 个研究点目标入组 28 人开始时间: 2019年1月17日最近更新: 2022年10月24日

适应症

试验速览

暂无简介。

•Greater than or equal to 18 years of age with a formal diagnosis of ulcerative colitis
•Mild-moderate ulcerative colitis disease activity as defined by a Mayo Score of 3-10 with a Mayo endoscopic sub-score of greater than or equal to 1
•Patients on stable therapy (or no therapy) for defined periods:
•No therapy for greater than or equal to 4 weeks
•Stable dose of oral and/or topical 5-aminosalicylic acid therapy for greater than or equal to 4 weeks
•Stable dose of immunomodulator therapy (azathioprine, mercaptopurine, or methotrexate) for greater than or equal to 8 weeks
•Stable dose of biologic therapy (infliximab, adalimumab, vedolizumab) for greater than or equal to 12 weeks
•Steroid refractory – on <20mg corticosteroids for greater than or equal to 4 weeks

•Quiescent ulcerative colitis disease activity as defined by a Mayo Score of less than or equal to 2 and/or a Mayo endoscopic sub-score of 0.
•Severely active UC as defined by a Mayo Score of greater than 10 and/or evidence of systemic toxicity (tachycardia, fever, C-reactive protein >40, Haemoglobin <110g/l).
•Patients with Crohn’s colitis
•Patients who are pregnant or breast feeding
•Patients with significant medical or cognitive/psychiatric comorbidities
•Patients who have undergone prior colonic surgery
•People currently receiving tapering corticosteroid therapy
•People with evidence of active infection and/or those requiring current antibiotic therapy
•People receiving dual antiplatelet therapy or anticoagulant therapy
•People who are unable to provide informed consent

发起方

niversity of Adelaide